M. Klompas and R. Platt, Ventilator-associated pneumonia-the wrong quality measure for benchmarking, Ann Intern Med, vol.147, pp.803-808, 2007.

D. Koulenti, E. Tsigou, and J. Rello, Nosocomial pneumonia in 27 ICUs in Europe: Perspectives from the EU-VAP/CAP study, Eur J Clin Microbiol Infect Dis, vol.36, pp.1999-2006, 2017.

L. P. Skrupky, K. Mcconnell, J. Dallas, and M. H. Kollef, A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians criteria, Crit Care Med, vol.40, pp.281-285, 2012.

D. J. Cook, S. D. Walter, R. J. Cook, L. E. Griffith, G. H. Guyatt et al., Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients, Ann Intern Med, vol.129, pp.433-473, 1998.

S. T. Micek, R. G. Wunderink, M. H. Kollef, C. Chen, J. Rello et al., An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: Impact of multidrug resistance, Crit Care, vol.19, p.219, 2015.

M. K. Von-cube, J. Timsit, H. Sommer, M. Darmon, C. Schwebel et al., Relative risk and population-attributable fraction of ICU death caused by susceptible and resistant Pseudomonas aeruginosa ventilator-associated pneumonia: A competing risks approach to investigate the OUTCOMEREA database, Intensive Care Med, vol.44, pp.1177-1186, 2018.

W. G. Melsen, M. M. Rovers, R. Groenwold, D. Bergmans, C. Camus et al., Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies, Lancet Infect Dis, vol.13, pp.665-71, 2013.

A. C. Kalil, M. L. Metersky, M. Klompas, J. Muscedere, D. A. Sweeney et al., Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the, Clin Infect Dis, vol.63, pp.61-111, 2016.

A. Magiorakos, A. Srinivasan, R. B. Carey, Y. Carmeli, M. E. Falagas et al., Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance, Clin Microbiol Infect, vol.18, pp.268-81, 2012.

C. Luyt, A. A. Lu, Q. Micaelo, M. Br-echot, N. Brossier et al., Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia, Antimicrob Agents Chemother, vol.58, pp.1372-80, 2014.
DOI : 10.1128/aac.02109-13
URL : https://aac.asm.org/content/58/3/1372.full.pdf

A. Torres, M. S. Niederman, J. Chastre, S. Ewig, P. Fernandez-vandellos et al., International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the, European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci on Latinoamericana del T orax (ALAT)

, Eur Respir J, vol.50, 2017.

J. Rello, D. A. Ollendorf, G. Oster, M. Vera-llonch, L. Bellm et al., Epidemiology and outcomes of ventilator-associated pneumonia in a large US database, Chest, vol.122, pp.2115-2136, 2002.

J. Rello, V. Ausina, M. Ricart, C. Puzo, E. Quintana et al., Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia, Intensive Care Med, vol.20, pp.193-201, 1994.

M. Bekaert, J. Timsit, S. Vansteelandt, P. Depuydt, A. V-esin et al., Attributable mortality of ventilator-associated pneumonia: A reappraisal using causal analysis, Am J Respir Crit Care Med, vol.184, pp.1133-1142, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00841199

M. Nguile-makao, J. Zahar, A. Français, A. Tabah, M. Garrouste-orgeas et al., Attributable mortality of ventilator-associated pneumonia: Respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models, Intensive Care Med, vol.36, pp.781-790, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00465413

F. Alvarez-lerma, Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group, Intensive Care Med, vol.22, pp.387-94, 1996.

C. Peña, S. Zorrilla, I. Oriol, F. Tubau, M. A. Dominguez et al., Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: Predictors of early and crude mortality, Eur J Clin Microbiol Infect Dis, vol.32, pp.413-433, 2013.

M. Tumbarello, D. Pascale, G. Trecarichi, E. M. Spanu, T. Antonicelli et al., Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients, Intensive Care Med, vol.39, pp.682-92, 2013.

V. Aloush, S. Navon-venezia, Y. Seigman-igra, S. Cabili, and Y. Carmeli, Multidrug-resistant Pseudomonas aeruginosa: Risk factors and clinical impact, Antimicrob Agents Chemother, vol.50, pp.43-51, 2006.

C. F. Pope, T. D. Mchugh, and S. H. Gillespie, Methods to determine fitness in bacteria, Methods Mol Biol, vol.642, pp.113-134, 2010.